In a shock, advisers to the Meals and Drug Administration on Thursday voted that the dangers tied to a blood most cancers drug from GSK outweighed the advantages it had demonstrated in trials, as issues about generally severe eye-related unwanted side effects and questions concerning the dose the corporate chosen dominated a listening to.
The FDA is about to resolve whether or not to approve the drug, referred to as Blenrep, by as quickly as subsequent week. The company usually follows its advisers’ suggestions, however doesn’t must.
In briefing paperwork launched earlier this week, company employees highlighted their issues concerning the ocular points and urged that decrease dosages of Blenrep may provide sufferers comparable efficacy in treating a number of myeloma whereas reducing the chance of unwanted side effects.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
